← 產業報告目錄

CGRP Inhibitor Market Size, Share & Trends Analysis Report By Treatment (Preventive, Acute), By Route of Administration (Oral, Nasal, Intravenous), By End-User (Hospitals, Pharmacies, Specialty Clinics), By Region, And By Segment Forecasts, 2025-2034

出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-15頁數 180報告編號 INSIGHTACE-a7182d1f5f

授權報價

Single User PDF$4,500 USD
Global Site License PDF$9,500 USD
洽詢購買 申請 Sample

報告摘要

In 2024, the CGRP Inhibitor Market worldwide was assessed at USD 3.3 Bn. Analysts project it will surge to USD 8.5 Bn by 2034, at a CAGR of 10.2% spanning 2025 to 2034. The CGRP Inhibitor sector involves often used as preventative therapies for constant migraines, offering a new and focused method of treating a disorder that has an enormous adverse effect on the standard of existen. This domain has witnessed considerable transformation owing to technological breakthroughs and shifting healthcare dynamics. Growth is bolstered by a convergence of factors: rising awareness among end users, continuous product innovation, and the expanding emphasis on efficiency and sustainability within the healthcare sector. From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities. Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region poised to deliver the strongest growth trajectory through the forecast period, bolstered by demographic shifts and policy support. Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing. Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global CGRP Inhibitor Market Snapshot Chapter 4. Global CGRP Inhibitor Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Investment and Funding Analysis 4.6. Porter's Five Forces Analysis 4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034 4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023) 4.9. Use/impact of AI on CGRP Inhibitor Market Industry Trends 4.10. Global CGRP Inhibitor Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034 Chapter 5. CGRP Inhibitor Market Segmentation 1: By Treatment, Estimates & Trend Analysis 5.1. Market Share By Treatment, 2024 & 2034 5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product Type: 5.2.1. Preventive 5.2.2. Acute Chapter 6. CGRP Inhibitor Market Segmentation 2: By Route of Administration, Estimates & Trend Analysis 6.1. Market Share By Route of Administration, 2024 & 2034 6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Source: 6.2.1. Oral 6.2.2. Nasal 6.2.3. Intravenous Chapter 7. CGRP Inhibitor Market Segmentation 3: By End-User, Estimates & Trend Analysis 7.1. Market Share By End-User, 2024 & 2034 7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-User: 7.2.1. Hospitals 7.2.2. Pharmacies 7.2.3. Specialty Clinics Chapter 8. CGRP Inhibitor Market Segmentation 5: Regional Estimates & Trend Analysis 8.1. Global CGRP Inhibitor Market, Regional Snapshot 2024 & 2034 8.2. North America 8.2.1. North America CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034 8.2.1.1. US 8.2.1.2. Canada 8.2.2. North America CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Treatment, 2021-2034 8.2.3. North America CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2021-2034 8.2.4. North America CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By End-User, 2021-2034 8.3. Europe 8.3.1. Europe CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034 8.3.1.1. Germany 8.3.1.2. U.K. 8.3.1.3. France 8.3.1.4. Italy 8.3.1.5. Spain 8.3.1.6. Rest of Europe 8.3.2. Europe CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Treatment, 2021-2034 8.3.3. Europe CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2021-2034 8.3.4. Europe CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By End-User, 2021-2034 8.4. Asia Pacific 8.4.1. Asia Pacific CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034 8.4.1.1. India 8.4.1.2. China 8.4.1.3. Japan 8.4.1.4. Australia 8.4.1.5. South Korea 8.4.1.6. Southeast Asia 8.4.1.7. Rest of Asia Pacific 8.4.2. Asia Pacific CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Treatment, 2021-2034 8.4.3. Asia Pacific CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2021-2034 8.4.4. Asia Pacific CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By End-User, 2021-2034 8.5. Latin America 8.5.1. Latin America CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034 8.5.1.1. Brazil 8.5.1.2. Mexico 8.5.1.3. Rest of Latin America 8.5.2. Latin America CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Treatment, 2021-2034 8.5.3. Latin America CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2021-2034 8.5.4. Latin America CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By End-User, 2021-2034 8.6. Middle East & Africa 8.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034 8.6.1.1. GCC Countries 8.6.1.2. Israel 8.6.1.3. South Africa 8.6.1.4. Rest of Middle East and Africa 8.6.2. Middle East & Africa CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Treatment, 2021-2034 8.6.3. Middle East & Africa CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2021-2034 8.6.4. Middle East & Africa CGRP Inhibitor Market Revenue (US$ Million) Estimates and Forecasts By End-User, 2021-2034 Chapter 9. Competitive Landscape 9.1. Major Mergers and Acquisitions/Strategic Alliances 9.2. Company Profiles 9.2.1. Eli Lilly and Company 9.2.1.1. Business Overview 9.2.1.2. Key Product Type/Service Overview 9.2.1.3. Financial Performance 9.2.1.4. Geographical Presence 9.2.1.5. Recent Developments with Business Strategy 9.2.2. Pfizer Inc 9.2.3. Teva Pharmaceutical Industries Ltd 9.2.4. AbbVie Inc. 9.2.5. Amgen Inc 9.2.6. Novartis AG 9.2.7. Allergan 9.2.8. Biohaven Pharmaceutical Holding Company Ltd. 9.2.9. Sun Pharmaceutical Industries Ltd 9.2.10. Lundbeck 9.2.11. AstraZeneca plc 9.2.12. F. HoffmannLa Roche Ltd 9.2.13. Bristol Myers Squibb Company 9.2.14. Other Market Players.

量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們